Synta Pharmaceuticals Corp.
Climate Impact & Sustainability Data (2008)
Reporting Period: 2008
Environmental Metrics
Climate Goals & Targets
Environmental Challenges
- Suspension of clinical development of lead drug candidate, elesclomol, due to potential safety concerns identified by an independent Data Monitoring Committee (DMC).
Mitigation Strategies
- Diligent assessment of the impact of the suspension on Synta’s business, plans for the future, and 2008 financial statements. Proceeding expeditiously to complete this work and finalize the Form 10-K.